Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and Methods: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed‐effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence ( n = 2257) was 28.2% (95% confidence interval [CI] 22.3–34.1), bladder cancer ( n = 1951) 24.7% (95% CI 19.1–30.2), UTUC ( n = 128) 1.14% (95% CI 0.77–1.52), renal cancer ( n = 107) 1.05% (95% CI 0.80–1.29), and prostate cancer ( n = 124) 1.75% (95% CI 1.32–2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03–1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90–4.15; P < 0.001), male sex 1.30 (95% CI 1.14–1.50; P < 0.001), and smoking 2.70 (95% CI 2.30–3.18; P < 0.001). Conclusions: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.
INTRODUCTION: Holmium laser enucleation of the prostate (HoLEP) has evidenced-based advantages in treating benign prostatic hypertrophy (BPH) relative to other interventions. Unfortunately, adoption of HoLEP has remained relatively low in Medicare and National Surgical Quality Improvement Program (NSQIP) populations. HoLEP’s role as an inpatient surgical intervention is changing as advancements in the technique and systems have demonstrated the feasibility of same-day discharge. Thus, our objective was to evaluate national HoLEP trends in ambulatory surgery settings from 2016-2019. METHODS: The Nationwide Ambulatory Surgery Sample (NASS) is the largest national all-payer database of ambulatory surgical encounters, managed by the Agency for Healthcare Research and Quality. A cross-sectional, retrospective analysis of the 2016 and 2019 NASS was performed. Rates of BPH surgeries were calculated and stratified by age, census region, and primary payer to compare across time-points for trends. Chi-squared and two-sample t-tests were completed for categorical and continuous variables, respectively. RESULTS: The total number of ambulatory BPH surgeries fell 20% between 2016 (n=124,538) and 2019 (n=100,593). In 2016, HoLEP lagged behind photo-selective vaporization of the prostate (PVP) and Transurethral Resection of Prostate (TURP) with 4.7% of surgeries, but rose to the second most-common procedure in 2019 with 8.3% of total surgeries. TURP was the most common intervention (62.6% in 2016, 90.7% in 2019). Simple prostatectomy was the most expensive intervention. By US census region, more HoLEPs were done in the South (43.1% in 2016, 37.5% in 2019) and Midwest (26.8% in 2016, 31.7% in 2019). CONCLUSION: Overall, HoLEP uptake is increasing. HoLEP has replaced greenlight PVP as the second-most frequently used intervention. The rate of ambulatory HoLEPs has nearly doubled despite a general decrease in the number of surgeries.
23 May 2013 in Acta Crystallographica Section F Structural Biology and Crystallization Communications
The type VI secretion system of Pseudomonas aeruginosa has been shown to be responsible for the translocation of bacteriolytic effectors into competing bacteria. A mechanistic understanding of this widely distributed secretion system is developing and structural studies of its components are ongoing. Two representative structures of one highly conserved component, TssJ, from Escherichia coli and Serratia marcescens have been published. Here, the X-ray crystal structure of TssJ1 from P. aeruginosa is presented at 1.4 Å resolution. The overall structure is conserved among the three proteins. This finding suggests that the homologues function in a similar manner and bolsters the understanding of the structure of this family of proteins.
Introduction: Holmium laser enucleation of the prostate (HoLEP) is routinely performed with a 24, 26, or a 28 French (F) scope. Proponents of the larger scopes propose that a bigger sheath size allows for superior flow and visibility leading to a more efficient operation and better hemostasis. Those utilizing the smaller scopes suggest the lower profile is less traumatic, resulting in lower stricture rates and temporary incontinence. We sought to compare outcomes of ambulatory HoLEP using the 24F and 28F laser scope. Materials and Methods: From May 2022 to March 2023, we randomized patients undergoing HoLEP (0.05) scopes. Procedural duration and efficiencies were not different between groups (all p>0.05). The 28F scope was associated with improved surgeon-graded irrigation flow and visibility (p0.05). Conclusions: We identified no clear advantage of scope size with regards to intra-operative or post-operative outcomes at 3-month follow up due to scope size. However, if same-day discharge is part of your postoperative pathway, the 28F scope may shorten length of stay and increase rates of successful same-day trial of void.